Johnson & Johnson (J&J) announced on Monday that it has agreed to pay an estimated $5.5 billion to settle approximately 76,000 lawsuits alleging that its baby powder and talc products caused ovarian cancer, potentially ending years of litigation on the matter [1]. The proposed settlement covers claims consolidated in federal court in New Jersey as well as related state court cases, addressing nearly all outstanding claims against the company [1]. J&J previously settled most cases alleging its talc contained asbestos and caused mesothelioma [1].
The settlement must be accepted by 95% of ovarian cancer claimants in state or federal court before it becomes final [1]. J&J denied any wrongdoing, stating that plaintiffs were unable to prove their claims and that the settlement is intended to efficiently resolve the litigation [1]. Erik Haas, J&J's worldwide VP of litigation, emphasized that the company believes it would have ultimately prevailed in further litigation but chose to settle to focus on its core mission [1].
J&J expects to pay out $3 billion in 2027, with additional payments in 2028, and the total settlement could exceed $7 billion depending on participation, as the agreement does not cap the total payout but assigns specific values to qualifying claims [1]. Chris Seeger, an attorney representing about 2,500 clients, stated that the plaintiffs received a fair settlement and expressed satisfaction with the outcome [1].
The settlement follows a series of courtroom victories for J&J, including individual trial wins, disqualification of plaintiffs' lawyers, and rulings against plaintiffs' experts. Last week, the company secured a significant court victory when a federal judge questioned the ability of individual plaintiffs to prove that talc specifically caused their ovarian cancer [1]. J&J has consistently denied that its talc products caused cancer, maintaining that the products were safe and asbestos-free. The company stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch-based product [1]. Previous attempts to resolve the litigation through bankruptcy filings by shell-company subsidiaries were unsuccessful [1].
CONCLUSION
Johnson & Johnson's $5.5 billion settlement aims to resolve the majority of outstanding talc-related lawsuits, providing closure to a decade-long legal battle. While the company maintains its products are safe, the settlement allows J&J to move forward and focus on its core business. The agreement carries significant financial implications, with the potential payout exceeding $7 billion depending on claimant participation.